Allianz Asset Management AG reduced its position in Prothena Co. PLC (NASDAQ:PRTA) by 69.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 9,628 shares of the biotechnology company’s stock after selling 21,715 shares during the period. Allianz Asset Management AG’s holdings in Prothena Co. PLC were worth $474,000 at the end of the most recent reporting period.
Several other large investors have also recently made changes to their positions in PRTA. BNP Paribas Arbitrage SA increased its stake in shares of Prothena Co. PLC by 26.0% in the third quarter. BNP Paribas Arbitrage SA now owns 5,091 shares of the biotechnology company’s stock worth $305,000 after buying an additional 1,052 shares during the last quarter. First Mercantile Trust Co. purchased a new stake in shares of Prothena Co. PLC during the third quarter worth about $210,000. HL Financial Services LLC purchased a new stake in shares of Prothena Co. PLC during the third quarter worth about $206,000. Strs Ohio purchased a new stake in shares of Prothena Co. PLC during the third quarter worth about $131,000. Finally, Aperio Group LLC purchased a new stake in shares of Prothena Co. PLC during the third quarter worth about $210,000.
Prothena Co. PLC (NASDAQ:PRTA) traded down 1.78% on Friday, hitting $52.95. 218,428 shares of the company’s stock traded hands. The stock has a 50 day moving average price of $53.15 and a 200-day moving average price of $53.66. The stock’s market cap is $1.85 billion. Prothena Co. PLC has a 12 month low of $33.53 and a 12 month high of $68.18.
Prothena Co. PLC (NASDAQ:PRTA) last released its quarterly earnings data on Tuesday, February 14th. The biotechnology company reported ($1.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.12) by $0.29. The business had revenue of $0.20 million for the quarter, compared to analyst estimates of $5.35 million. Prothena Co. PLC had a negative return on equity of 32.65% and a negative net margin of 11,365.41%. The company’s revenue was down 35.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.76) earnings per share. Equities analysts predict that Prothena Co. PLC will post ($5.07) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Allianz Asset Management AG Has $474,000 Position in Prothena Co. PLC (PRTA)” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://sportsperspectives.com/2017/04/21/prothena-co-plc-prta-shares-sold-by-allianz-asset-management-ag-updated-updated.html.
PRTA has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Prothena Co. PLC from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a report on Tuesday, January 3rd. Wedbush reissued an “outperform” rating and issued a $77.00 price target on shares of Prothena Co. PLC in a report on Wednesday, February 15th. Nomura initiated coverage on shares of Prothena Co. PLC in a research note on Wednesday, March 1st. They issued a “buy” rating on the stock. Instinet initiated coverage on shares of Prothena Co. PLC in a research note on Wednesday, March 1st. They issued a “buy” rating and a $87.00 target price on the stock. Finally, Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of Prothena Co. PLC in a research note on Wednesday, March 22nd. Twelve research analysts have rated the stock with a buy rating, Prothena Co. PLC has an average rating of “Buy” and an average price target of $75.09.
In other news, CFO Tran Nguyen bought 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 9th. The stock was purchased at an average cost of $51.32 per share, with a total value of $51,320.00. Following the transaction, the chief financial officer now directly owns 3,200 shares in the company, valued at $164,224. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Karin L. Walker sold 5,000 shares of the company’s stock in a transaction dated Monday, April 17th. The shares were sold at an average price of $52.25, for a total value of $261,250.00. Following the completion of the sale, the insider now directly owns 3,000 shares of the company’s stock, valued at $156,750. The disclosure for this sale can be found here. 3.70% of the stock is owned by corporate insiders.
Prothena Co. PLC Company Profile
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Receive News & Ratings for Prothena Co. PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Co. PLC and related companies with MarketBeat.com's FREE daily email newsletter.